Table 1. Characteristics of ovarian cancer case-control populations analyzed in this study.
| Study | Country | Controls | Cases | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Number | Mean age(range) | Number | Mean age(range) | High-grade serousd |
(%) | Stage3/4 | (%)d | ||
| AOC | Australia | 629 | 57 (20-80) | 589 | 61 (23-80) | 516 | (88) | 515 | (88) |
| CAMc | UK | 0 | NA | 325 | 64 (19-90) | 196 | (60) | 237 | (79) |
| GRRa | USA | 0 | NA | 124 | 49 (21-83) | 50 | (40) | NA | |
| HJO/HMO | Germany/Belarus | 519 | 36 (18-68) | 341 | 58 (18-88) | 107 | (32) | 153 | (45) |
| ICNc | UK | 0 | NA | 422 | 57 (24-79) | 293 | (69) | 31 | (86) |
| LAX | USA | 209 | 62 (34-90) | 175 | 62 (32-88) | 175 | (100) | 159 | (92) |
| MAY | USA | 660 | 63 (26-93) | 650 | 64 (23-91) | 630 | (97) | 581 | (89) |
| RMHb | UK | 0 | NA | 61 | 53 (27-73) | 61 | (100) | NA | |
| SEA | UK | 835 | 53 (29-66) | 700 | 57 (24-74) | 349 | (50) | 388 | (70) |
| SROc | UK | 0 | NA | 627 | 57 (18-84) | 318 | (51) | 507 | (81) |
| STA | USA | 147 | 48 (20-64) | 151 | 53 (23-64) | 116 | (77) | 111 | (74) |
| UKO | UK | 369 | 65 (52-78) | 353 | 61 (25-90) | 267 | (75) | 242 | (72) |
| Total | 3,368 | 55 (18-93) | 4,508 | 59 (18-91) | 3,017 | (67) | 2,924 | (81) | |
All studies are case-control studies except for: a familial ovarian cancer registry study, b case only hospital study and c case only clinical trial; d % of those with known stage